Is the proposed systematic review or network meta‑analysis title on elective stage I–III right‑ or left‑sided colon cancer, excluding emergency obstruction, perforation, trauma, inflammatory bowel disease, and rectal cancer, novel and likely to have significant impact?

Assessment of Research Novelty and Impact

A systematic review or network meta-analysis on elective stage I–III right- or left-sided colon cancer (excluding emergency presentations) would have limited novelty and moderate impact, as the evidence base for elective colon cancer management is already well-established through multiple high-quality guidelines and recent meta-analyses.

Current Evidence Landscape

The proposed research question addresses a clinical area that is already extensively covered by existing literature:

Established Guidelines and Evidence

For elective colon cancer management, the evidence base is mature and comprehensive:

• The 2024 NCCN Colon Cancer Guidelines 1 provide detailed, evidence-based recommendations for stage I–III disease, including treatment algorithms based on tumor sidedness, molecular markers, and stage-specific considerations
• The 2022 ASCO Guidelines 2 specifically address adjuvant therapy for stage II colon cancer with clear, evidence-based recommendations stratified by risk factors
• Multiple recent systematic reviews and meta-analyses have already synthesized the surgical and oncological outcomes for both right- and left-sided colon cancer 3, 4, 5, 6

Where the Evidence Gap Actually Exists

The true knowledge gap lies in emergency presentations, not elective cases:

• The 2019 World Journal of Emergency Surgery guideline review 7 explicitly concluded that "there is a lack of high-quality evidence to support whether emergency surgery or stenting as a bridge to surgery is the optimal procedure in terms of morbidity, mortality and long-term oncological outcome"
• The 2018 WSES Guidelines 8 noted that "international guidelines offer limited and contrasting recommendations on the management of left-sided MBO" (malignant bowel obstruction)
• Emergency presentations account for approximately 20-30% of colorectal cancer cases 8, representing a substantial clinical burden with genuine equipoise

Why Elective Cases Have Limited Novelty

The elective colon cancer literature is saturated with high-quality evidence:

• Surgical technique: Complete mesocolic excision (CME) has been extensively studied with multiple recent meta-analyses 3, 4 showing improved lymph node harvest and potential survival benefits in stage III disease
• Anastomotic techniques: A 2026 meta-analysis of 33 RCTs with 3,787 patients 5 comprehensively compared access routes and anastomotic techniques
• Tumor sidedness: The prognostic and predictive value of primary tumor location is well-established 1, with clear treatment algorithms based on molecular subtyping
• Adjuvant therapy: Stage-specific and risk-stratified recommendations are clearly defined 2

Potential Impact Considerations

A systematic review on elective cases would likely:

• Duplicate existing work: The clinical questions have been answered by multiple recent guidelines and meta-analyses
• Provide incremental value only: Any new synthesis would primarily update existing evidence rather than address genuine clinical equipoise
• Miss the real opportunity: The emergency obstruction/perforation scenario is where clinical uncertainty and practice variation persist

Where Impact Could Be Maximized

If you want significant impact, consider instead:

1. Emergency presentations with obstruction/perforation: This is where 7 explicitly identified the evidence gap
2. Bridge-to-surgery strategies: The 2021 AGA guideline 9 and recent 2026 network meta-analysis 10 show this remains an evolving area with ongoing debate
3. Patient selection for extended lymphadenectomy: The 2026 systematic review 11 identified that "patient selection criteria remain poorly defined" despite two decades of research

Critical Caveats

Before proceeding with any systematic review:

• Search PROSPERO and other registries to ensure your specific question hasn't been registered or recently completed
• The exclusion of emergency cases removes the population with the greatest evidence gap and clinical uncertainty
• The 2026 publications 5, 10, 11 suggest the field is actively producing high-quality syntheses, making timing critical for novelty

Bottom line: Your proposed scope (elective stage I–III, excluding emergencies) targets a well-studied population with established guidelines. The excluded population (emergency obstruction/perforation) is where genuine clinical equipoise exists and where a high-quality systematic review could have substantial impact on practice 7, 8, 7.